Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease - Wikidata - awgldk - TriplyDB

Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

http://www.wikidata.org/entity/Q36276997

about

MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11 The IkappaB kinase complex: master regulator of NF-kappaB signaling Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review Innate Immune Response in Brain, NF-Kappa B Signaling and Cystatins Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders Ankyrin repeat and BTB/POZ domain containing protein-2 inhibits the aggregation of alpha-synuclein: implications for Parkinson's disease A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin.Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo.Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide.Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models.Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice.Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses.Enhancement of morphological plasticity in hippocampal neurons by a physically modified saline via phosphatidylinositol-3 kinase.A physically-modified saline suppresses neuronal apoptosis, attenuates tau phosphorylation and protects memory in an animal model of Alzheimer's disease.Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases.MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA.Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease.Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.Cell penetrating peptide inhibitors of nuclear factor-kappa B.Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: a role of NADPH oxidase 2.Does Huntingtin play a role in selective macroautophagy?Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease.Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy.Prospects of statins in Parkinson disease Inflammatory stimuli induce inhibitory S-nitrosylation of the deacetylase SIRT1 to increase acetylation and activation of p53 and p65 Can cinnamon bring aroma in Parkinson's disease treatment?Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia.Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling.Absence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonism

P2860

Q24289060-29907D45-7E7F-4F5D-970D-BE6599862940 Q24313366-5925F7D9-34CE-4B5D-BC1E-18BECAAAF07B Q24629942-F753F9B2-FDE2-48A7-91B1-F7D84B9F2689 Q26747508-0CF4693B-D3B7-4F48-A236-34E6AC05528E Q26748974-10C434BC-E2AA-4920-8E99-BD1CE18C7AB1 Q26770760-3922F50B-BA56-473F-8E7D-97FB0796ED83 Q26773162-0B05D2DB-84E4-48AC-84C0-9D830BD9FAF2 Q26801035-97E58DE0-2D20-4887-AC8E-95CD076D22CB Q27027973-96532B37-3D80-446E-99C0-E19AB1B854F0 Q27301885-C2B10824-7299-4086-854E-05E13A49B395 Q28386662-1A24C476-6953-43BF-ADA9-C984F59CDAFF Q28505185-F4389786-3AB1-4D9D-8DA7-6EE9AB0897BD Q28538467-16B186AA-9BF1-4A59-B924-81C387A3E7BF Q28577454-4EA4CA08-0BE7-4334-8C3C-E83F2128917E Q33458331-4B7B4C1A-644F-4452-A9C8-565E268788CF Q33557852-A3BAFE15-E874-4188-865F-7B5908E931D9 Q33608424-C200553D-6F98-4C6F-B40F-88D93BDB18E2 Q33680232-1A515EBE-D915-425E-A67F-6EA11BDD8476 Q33793585-3752447F-323E-4463-963D-E5B3C7AB56B6 Q33795121-D257C82A-042E-40F3-B16D-1E28533F8A06 Q33797938-81A869E9-F53C-4209-8DFC-96D15DDD3D06 Q33822381-ABE39DE2-0C4B-4B5C-A09F-6BE88EEFD127 Q33875311-200668BE-5EF0-45D3-BDA0-42BBD2CF9C09 Q33999486-CF0EA38B-7AF6-4CDF-9EC2-DD2E905ACBED Q34027672-C8F834B6-18D9-4501-8EE8-181C76354114 Q34197681-8E07C31E-36A4-4A8A-87AC-D0355E848765 Q34205454-1F4A00E6-37F2-465F-A8D8-EC61A65BEF47 Q34287439-C29324A0-1830-4E1C-8159-9F4F6E74DA50 Q34289086-9FFB747C-4836-4C88-9891-4BED4BBD5252 Q34570989-01FC6776-8F51-4E14-87C0-98FDEBE6F848 Q34618914-19993C68-FE4C-4F43-8985-6DDEFF7A6897 Q34835467-9A6AA629-FE90-461D-A058-5DA08C532BBF Q34983243-55A697E8-8B48-4970-9D22-971599364EBA Q35016939-3236BDFC-65B9-4471-8A9B-6FB1604C290D Q35094028-9DBC60B4-6963-4A3D-8016-622568C72597 Q35121810-B54F84F1-1371-4B9B-B6A0-51FCFEF108A3 Q35169915-A278EC91-A9F5-43E2-B764-448782957352 Q35227444-D02161BC-840D-47B6-B2DC-3357F3F4EEBF Q35386499-7D674EE6-740F-4CE5-9511-176F496B8B44 Q35587423-8FE73DE9-532C-482F-8F9D-359D011F473B

P2860

Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

http://www.wikidata.org/entity/Q36276997

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Selective inhibition of NF-kap ...... e model of Parkinson's disease

@ast

Selective inhibition of NF-kap ...... e model of Parkinson's disease

@en

type

label

Selective inhibition of NF-kap ...... e model of Parkinson's disease

@ast

Selective inhibition of NF-kap ...... e model of Parkinson's disease

@en

prefLabel

Selective inhibition of NF-kap ...... e model of Parkinson's disease

@ast

Selective inhibition of NF-kap ...... e model of Parkinson's disease

@en

P1433

Q36276997-E2CFC833-F665-45A9-BE78-7C278D8B4FE8

P1476

Q36276997-69C27CDB-A352-4F6F-A3FA-B1ECAC96935F

P2093

Q36276997-0044B525-80AA-4D9A-8FA1-D01BD6A3E04B

Q36276997-14C847F3-DAE7-4992-B036-763685D627A0

Q36276997-3124B200-9C07-4A13-8A60-63B34AB4E368

Q36276997-56C0E022-9474-4A9B-A55E-A1F5712E1B9B

Q36276997-5E15EF77-E0EA-491D-BEE4-DA69C9578DB3

Q36276997-71CBC4D1-3800-4B63-BF13-81DFB213834C

Q36276997-88F9F8FA-D056-47C7-99E1-A7E63354230A

Q36276997-D53B50FF-2AB5-487E-9C71-AEB1ED28D365

Q36276997-ED47E361-8F03-40E6-B924-2C6E5F39F399

P2860

Q36276997-12706052-3626-4B65-B92E-5F56AE7B790F

Q36276997-1F20ADD6-4D7D-4716-AAD3-673AE16222B8

Q36276997-1F57753B-8BDC-429D-9BBF-AAAE7D55F232

Q36276997-296D8C78-4933-48B6-86DC-429684DD0067

Q36276997-634637A6-13F1-4A33-B62D-0FFC68F50C8C

Q36276997-64A60567-E603-44B3-B71C-CB3A50988B22

Q36276997-6DA2F4E8-C6D9-4802-A5BF-DE74CD81927A

Q36276997-6EC4C63D-3632-4A30-A051-F7BAF8485E4A

Q36276997-70D4A038-37BE-46CB-AD28-D3762AD264CB

Q36276997-7100163C-F1EC-42A5-96D0-41EC19DF7ACA

P304

Q36276997-32F91398-7B27-4DFE-BE6F-B05AAC48C851

P31

Q36276997-209A98F2-0EA7-4408-B278-D008A4B31D96

P356

Q36276997-0457B02C-5612-4175-A943-32E1ED327B5F

P407

Q36276997-CA919EAA-8736-4688-8884-4C02961360C8

P433

Q36276997-F8D7F499-9851-4201-8A4D-3CB356362F7C

P478

Q36276997-6BA222E9-AA22-46DF-8C91-60604E1B3E23

P50

Q36276997-2C83F263-B7A6-4369-A5FA-8E75BC4F3FF0

P577

Q36276997-662D6B7D-80F5-4BEF-951B-64F33BD66EF3

P5875

Q36276997-CA6356B5-0F01-4040-831A-BFDAD333ADF9

P698

Q36276997-A123C1BA-671A-4B2F-9B6C-AF8FC642274F

P921

Q36276997-0A8B7943-BCBB-4C9F-9143-266D408DD709

Q36276997-66545F70-1D74-4E07-BC02-D577BC9BAD45

Q36276997-D3FD617A-1769-4332-88A7-0805245A2769

P932

Q36276997-BB8046C7-AFF0-47AB-B5FD-EEB1CB5C87AA

P356

PNAS.0704908104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Selective inhibition of NF-kap ...... e model of Parkinson's disease

@en

P2093

Anamitra Ghosh

http://www.w3.org/2001/XMLSchema#string

Avik Roy

http://www.w3.org/2001/XMLSchema#string

Dean M Hartley

http://www.w3.org/2001/XMLSchema#string

Elliott J Mufson

http://www.w3.org/2001/XMLSchema#string

Howard E Gendelman

http://www.w3.org/2001/XMLSchema#string

Kalipada Pahan

http://www.w3.org/2001/XMLSchema#string

R Lee Mosley

http://www.w3.org/2001/XMLSchema#string

Sankar Ghosh

http://www.w3.org/2001/XMLSchema#string

Xiaojuan Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease

Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex

Parkinson's disease: mechanisms and models

Signaling to NF-kappaB

NF-kappaB at the crossroads of life and death

Etiology and pathogenesis of Parkinson's disease.

Microglia as mediators of inflammatory and degenerative diseases.

Changes in cytokines and neurotrophins in Parkinson's disease.

Novel anti-inflammatory therapy for Parkinson's disease.

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

P304

18754-18759

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0704908104

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey H Kordower

P577

2007-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5847011

http://www.w3.org/2001/XMLSchema#string

P698

18000063

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2141849

http://www.w3.org/2001/XMLSchema#string